Vascular calcification in chronic kidney disease: Role of disordered mineral metabolism

Current Pharmaceutical Design

Volumn 20, Issue 37, 2014, Pages 5829-5833

  Palit, Shyamal ^a   Kendrick, Jessica ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; Mineral metabolism; Phosphorus; Vascular calcification

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; FIBROBLAST GROWTH FACTOR 23; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KLOTHO PROTEIN; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER; VITAMIN D;

ARTICLE; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DYSLIPIDEMIA; HOMEOSTASIS; HUMAN; HYPERPHOSPHATEMIA; MINERAL METABOLISM; MORBIDITY; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; ANIMAL; CHRONIC KIDNEY FAILURE; COMPLICATION; METABOLISM;

ANIMALS; CALCIUM; HOMEOSTASIS; HUMANS; PHOSPHORUS; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION;

EID: 84911498740     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140212194926     Document Type: Article

References (68)

1. Hunt JL, Fairman R, Mitchell ME, et al. Bone formation in carotid plaques: a clinicopathological study. Stroke 2002; 33: 1214-9.
2. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75: 890-7.
3. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-83.
4. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38(4): 938-42.
5. rd Edition. Philadelphia, PA: Mosby Elsevier; 2007: 123-40.
6. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701.
7. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation cause familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14: 385-90.
8. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification hemodialysis patients. Nephrol Dial Transplant 2010; 25: 2679-85.
9. Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-hemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009; 24: 948-55.
10. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-30.
11. Adeney KL, Siscovick DS, Ix JH, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009; 20: 381-7.
12. Kendrick J, Chonchol M. The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis 2011; 58: 826-34.
13. Giachelli CM, Speer M, Li X, et al. Regulation of vascular calcification, roles of Phosphate and Osteopontin. Circ Res 2005; 96: 717-22.
14. Tyson KL, Reynolds JL, McNair R, et al. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003; 23: 489-94.
15. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-7.
16. Sugitani H, Wachi H, Murata H, et al. Characterization of an in vitro model of calcification in retinal pigmented epithelial cells. J Atheroscler Thromb 2003; 10: 48-56.
17. Chen NX, O'Neill KD, Duan D, Moe SM. Phosphorus and uremic serum upregulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002; 62: 1724-31.
18. Proudfoot D, Skepper J, Hegyi L, et al. Apoptosis regulates human vascular calcification in vitro. Evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000; 87: 1055-62.
19. Wada T, McKee MD, Stietz S, Giachelli CM. Calcification of vascular smooth muscle cell cultures: Inhibition by osteopontin. Circ Res 1999; 84: 1-6.
20. Mansfield K, Rajpurohit R, Shapiro IM. Extracellular phosphate ions cause apoptosis of terminally differentiated epiphyseal chondrocytes. J Cell Physiol 1999; 179: 276-86.
21. Mansfield K, Pucci B, Adams CS, Shapiro IM. Induction of apop-tosis in skeletal tissues: phosphate-mediated chick chondrocyte apoptosis is calcium dependent. Calcif Tissue Int 2003; 73: 161-72.
22. Son BK, Kozaki K, Iijima K, et al. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring gas6-axl survival pathway. Circ Res 2006; 98: 1024-31.
23. Shavelle Dm, Takasu J, Budoff MJ, et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002; 359: 1125-6.
24. Callister TQ, Raggi P, Cooil B, et al. Effect of HMG-CoA reeducates inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998; 339: 1972-8.
25. Massy ZA, Mentaverri R, Mozar A, et al. The pathophysiology of vascular calcification: are osteoclast-like cells the missing link? Diabetes Metab 2008; 34: S16-20.
26. Doherty TM, Uzui H, Fitzpatrick LA, et al. Rationale for the role of osteoclast-like cells in arterial calcification. FASEB J 2002; 16: 577-82.
27. Mozar A, Haren N, Chasseraud M, et al. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells. J Cell Physiol 2008; 215: 47-54.
28. Ewence AE, Bootman M, Roderick HL, et al. Calcium phosphate crystals induce cell death in human svascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res 2008; 103: e28-34.
29. Ohanian J, Gatfield KM, Ward DT, Ohanian V. Evidence for a functional calcium-sensing receptor that modulates myogenic tone in rat subcutaneous small arteries. Am J Physiol Heart Circ Physiol 2005; 288: H1756-62.
30. Alam MU, Kirton JP, Wilkinson Fl, et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 2009; 81: 260-8.
31. Sage AP, Lu J, Tintut Y, Demer LL. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int 2011; 79: 414-22.
32. McIntyre CW. Calcium balance during hemodialysis. Semin Dial 2008; 21: 38-42.
33. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; (113): S1-130.
34. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383-92.
35. Fritsch S, Lindner V, Welsch S, et al. Intravenous delivery of PTH/PTHrp type 2 receptor cDNA to rats decreases heart rate, blood pressure, renal tone, renin angiotensin system, and stress-induced cardiovascular responses. J Am Soc Nephrol 2004; 15: 2588-600.
36. Heyliger A, Tangpricha V, Weber C, Sharma J. Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism. Surgery 2009; 146: 1042-7.
37. Smith JC, Page MD, John R, et al. Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85: 3515-9.
38. Bleyer AJ, Burkart J, Piazza M, et al. Changes in cardiovascular calcification after parathyroidectomy in patients with ESRD. Am J Kidney Dis 2005; 46: 464-9.
39. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE Study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327-39.
40. EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-94.
41. Kendrick J, Cheung AK, Kaufman J, et al. Associations of plasma 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. Am J Kidney Dis 2012; 60: 567-75.
42. London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18(2): 613-20.
43. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrom-botic disease: from genes to treatment. Arch Intern Med 2003; 163: 1155-64.
44. Zoccali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 2006; 17: S169-73.
45. Somjen D, Weisman Y, Kohen F, et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111: 1666-71.
46. Shalhoug V, Shatzen E, Henley C, et al. Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif Tissue Int 2006; 79: 431-42.
47. Wu-Wong JR, Noonan W, Ma J, et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther 2006; 18: 90-8.
48. Rebsamen MC, Sun J, Norman AW, Liao JK. 1alpha, 25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002; 91: 17-24.
49. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007; 20(4): 302-8.
50. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359(6): 584-92.
51. Kendrick J, Cheung A, Kaufman J, et al. FGF-23 associates with death, cardiovascular events and dialysis initiation. J Am Soc Nephrol 2011; 22(10): 1913-22.
52. Gutierrez O, Januzzi J, Isakova T, et al. Fibroblast growth factor-23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-52.
53. El-Abbadi MM, Pai AS, Leaf EM, et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 2009; 75: 1297-307.
54. Nasrallah MM, El-Shehaby AR, Salem MM, et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification hemodialysis patients. Nephrol Dial Transplant 2010; 25: 2679-85.
55. Balci M, Kirkpantur A, Gulbay M, Gurbuz OA. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int 2010; 14: 425-32.
56. Tamei N, Ogawa T, Ishida H, et al. Serum fibroblast growth factor-23 levels and progression of aortic arch calcification in nondiabetic patients on chronic hemodialysis. J Atheroscler Thromb 2011; 18: 217-23.
57. Scialla JJ, Lau WL, Reilly WP, et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int2013; 83: 1159-68.
58. Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124-36.
59. Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Bio-phys Res Commun 2001; 280: 1015-20.
60. Kuroo M, Matsamura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
61. Chue CD, Townend JN, Moody WE, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 2013; 24: 842-52.
62. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-52.
63. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-24.
64. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255-61.
65. Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-65.
66. Barreto DV, Barreto Fde C, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification-results from the BRiC Study. Nephron Clin Pract 2008; 110: c273-83.
67. Ivanovski O, Nikolov IG, Joki N, et al. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis 2009; 205: 55-62.
68. Kawata T, Nagano N, Obi M, et al. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 2008; 74: 1270-7.